OOIR: Observatory of International Research

Papers

(The TQCC of Therapeutic Advances in Psychopharmacology is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Prevalence and predictors of inappropriate prescribing in outpatients with severe mental illness	105
Relationship between resilience and mental health among COVID-19 bereaved people: the mediating role of dual process coping	56
Biological markers of treatment response to serotonergic psychedelic therapies: a systematic review	46
History repeating: guidelines to address common problems in psychedelic science	39
Comment on: History repeating: guidelines to address common problems in psychedelic science	27
The missing link? Pharmacists’ perspectives on discontinuation of long-term antidepressants: a qualitative study	26
A rapid clinical response to etifoxine in treatment-resistant obsessive-compulsive disorder: a case report of a patient with comorbid bipolar disorder	26
Disrupted emotion regulation and spontaneous neural activity in panic disorder: a resting-state fMRI study	25
Incidence of hyperthyroidism in patients with bipolar or schizoaffective disorder with or without lithium: 21-year follow-up from the LiSIE retrospective cohort study	24
Psychotropic medications versus non-pharmacologic approaches for managing behavioural and psychological symptoms in Australian aged care residents with dementia: general practitioners’ and physicians’	23
Adult psychiatrists’ views on clozapine prescribing for schizophrenia in Germany—an online survey	22
Corrigendum to “Managing medical and psychiatric multimorbidity in older patients”	20
Reasons for discontinuing and restarting lithium multiple times: a case-register study based on the South London and Maudsley NHS Foundation Trust Clinical Record Interactive Search system	19
Plain Language Summary of Publication: A comparison of once-monthly and once-every-2-months injectable formulations of aripiprazole in people with schizophrenia	17
Sympathetic activation but not dissociation linked to ketamine’s sustained antidepressant effect	17
A description of antipsychotic prescribing patterns on the inpatient behavioral health setting: a multicenter cross-sectional analysis	17
Monoclonal antibody precision therapy targeting inflammation for bipolar disorder: a narrative review	15
Antipsychotics and structural brain changes: could treatment adherence explain the discrepant findings?	14
Safety and tolerability of intramuscular and sublingual ketamine for psychiatric treatment in the Roots To Thrive ketamine-assisted therapy program: a retrospective chart review	14
Adjunctive treatment with evenamide, a glutamate modulator, is associated with clinically meaningful benefits in patients with treatment-resistant schizophrenia and inadequate response to antipsychoti	14
Novel psychedelic interventions for post-traumatic stress disorder and their promise for precision medicine	11
Corrigendum to “Pharmacotherapy for post-traumatic stress disorder: systematic review and meta-analysis”	11
Impact of CYP1A , CYP2C19 , CYP2D6 ,	10
Psychedelic therapy and postpartum depression: priorities and prospects	9
Hypercoagulable state in patients with schizophrenia: different effects of acute and chronic antipsychotic medications	9

The interplay between serotonin syndrome and syndrome of inappropriate antidiuresis: a fatal case of acute hyponatremia during treatment with duloxetine, chlorphenamine, amitriptyline, and L-tryptopha	9
Sex, drugs, and arousal—two randomized trials on the effects of ketamine on sexual arousal and calcarine gyrus activity	9
Healthcare resource savings from administering paliperidone palmitate once every 3 months instead of once every month for schizophrenia: a 12-month mirror-image analysis of real-world population-based	9
Corrigendum to ‘Comment on: History repeating: guidelines to address common problems in psychedelic science’	9
Exploring the clinical factors affecting lithium dose and plasma level and the effect of brand	9
Effects of glucagon-like peptide-1 receptor agonists on psychiatric disorders: a systematic review	8
Comparative effectiveness study of paliperidone palmitate 6-month with a real-world external comparator arm of paliperidone palmitate 1-month or 3-month in patients with schizophrenia	8
Long-acting injectable antipsychotics for the treatment of bipolar disorder: evidence from mirror-image studies	8
Anticholinergic action is rarely a good thing	7
Patient views on paliperidone palmitate 3-monthly: a cross-sectional questionnaire in UK community mental health teams	7
Adjunctive aripiprazole for amisulpride-induced hyperprolactinemia: a preliminary retrospective study showing no reversing effect	7
The role of empathy in antidepressant withdrawal	7